Summary: Abyssinia Biosciences and Cordance Medical are collaborating to explore focused ultrasound technologies for early detection and enhanced delivery of therapeutic antibodies in Alzheimer’s disease.

Key Takeaways

  • Focused ultrasound is being explored for early detection and treatment of Alzheimer’s disease, using technologies like SonoBiopsy for identifying toxic amyloid abnormalities and SonoScript for enhancing antibody delivery.
  • The collaboration aims to improve the efficacy and safety of Aβ immunotherapy, focusing on non-invasive liquid biopsies and targeted brain delivery methods.
  • The partnership supports research on BBB opening and biomarker development, aligning with efforts to optimize therapeutic antibody exposure and early-stage Alzheimer’s treatment strategies.

————————————————————————————————————————————————————————————

Abyssinia Biosciences and Cordance Medical have entered into a collaborative agreement to explore the use of focused ultrasound in diagnostic and therapeutic applications for Alzheimer’s disease.

The collaboration will focus on the early identification of toxic amyloid abnormalities in Alzheimer’s disease using Cordance Medical’s ultrasound-mediated SonoBiopsy technology. Additionally, Cordance’s SonoScript technology will be investigated for its potential to enhance the brain biodistribution of Abyssinia’s antibodies.

“Ultrasound-guided drug delivery is an emerging method to improve the efficacy and safety of Aβ immunotherapy,” says Bhaskar Ramamurthy, CEO and co-founder of Cordance. “In addition to its potential to obtain liquid biopsies from brain tissue non-invasively, focused ultrasound should be further explored as one of the safest methods for monoclonal antibody brain delivery and targeted delivery to disease-relevant brain areas.”

Supporting Education in Nuclear Medicine Technology

Frederic Godderis, co-founder and CEO of Abyssinia Biosciences, also spoke out about the partnership, commenting:  “Now that Aβ immunotherapy has been shown to slow cognitive decline in mild to moderate stages of Alzheimer’s disease, addressing the earliest stages of the disease becomes the next key goal.”

“This partnership allows us to evaluate the effects of higher exposures of our therapeutic antibodies in preclinical Alzheimer’s disease models and to explore the potential of BBB opening for biomarker development. It also aligns with our ongoing work on shuttle technologies to optimize BBB penetration and biomarker development.”